Date: 13.11.2026

To,
The Secretary,
Listing Department
BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Sub.:	**Outcome of the Board Meeting held on Friday, November 13, 2026**
Ref.:	**Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**
Scrip Code:	**524723**
ISIN:	**INE491D01017**

Respected Authorities,

Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, November 13, 2026, has, inter-alia, considered, approved and taken on record the following:

1. The Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half Year ended September 30, 2026, as reviewed and recommended by the Audit Committee.
2. The Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half Year ended September 30, 2026, prepared in terms of Regulation 33 of the SEBI Listing Regulations, together with the Limited Review Report of the Statutory Auditors along with the Statement of Assets and Liabilities and Cash Flow Statement for the half year ended September 30, 2026, are enclosed herewith **(Annexure-A)**.
3. Disclosure of Related Party Transactions as per Regulation 23(9) of the SEBI Listing Regulations in the prescribed format for the half year ended September 30, 2026 is being filed as a part of Integrated Filling (Financials) with BSE through XBRL mode.

The results are also being uploaded on the Company's website at www.arvayahealth.com

Moreover, in terms of the requirements of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, and the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Company's Securities, which was closed from Thursday, October 01, 2026, for all Designated Persons and their

immediate relatives, will open 48 hours after the declaration of the aforesaid Financial Results, i.e. from Monday, November 16, 2026 onwards.

The Board meeting commenced at 4:42 p.m. IST and concluded at 6.10 p.m. IST

This is for your records and information.

Thanking you,

Yours faithfully,
For Arvaya Healthcare Limited
(formerly known as Bijoy Hans Limited)

KAUSHAL UTTAM SHAH
Digitally signed by KAUSHAL UTTAM SHAH
Date: 2026.11.13 18:47:41 +05'30'

Kaushal Shah
Managing Director
DIN: 02175130

Encl.: a/a

Independent Auditor's Review Report on Unaudited Standalone Financial Results of Arvaya Healthcare Limited (Formerly Known as Bijoy Hans Limited) for the Quarter and Half Year ended 30th September 2026, pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Arvaya Healthcare Limited
(Formerly Known as Bijoy Hans Limited)

Introduction

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of ARVAYA HEALTHCARE LIMITED (Formerly Known as Bijoy Hans Limited) ("the Company") for the quarter and half year ended 30th September 2026, together with the notes thereon ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 (as amended) read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

4. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Standalone Financial Results has not been prepared in accordance with recognition and measurement principles laid down in the aforesaid Ind AS 34 and other accounting principles generally accepted in India, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For
KHIRE KHANDEKAR & KIRLOSKAR
CHARTERED ACCOUNTANTS
FRN: 105148W

KEDAR GAJANAN PHATAK
Digitally signed by KEDAR GAJANAN PHATAK
Date: 2026.11.13 15:55:39 +05'30'

KHIRE KHANDEKAR & KIRLOSKAR
CA
FRN-105148W
SANGLI
CHARTERED ACCOUNTANTS

K. G. PHATAK
Partner
M. No.: 104106
Place: Sangli
Date: 13/11/2026
UDIN: 26104106XBRLVM9692

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS LIMITED)

CIN: L86100AS1985PLC002323

Reg. Office- NIRVANA Co Working Spaces, Mezzanine floor, Itag Plaza, ABC, G S Road, Guwahati, Dispur, Kamrup, Gmc, Assam , India 781005
Ph No: +91 7066670199 Email: compliance@arvayahealth.com Website:www.arvayahealth.com

Unaudited Standalone Financial Results For The Quarter & Half Year Ended 30th September, 2026

(₹ in Lacs)

SR No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Q2 30-09-2026	Q1 30-06-2026	Q2 30-09-2025	30-09-2026	30-09-2025	31-03-2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	**Revenue from operations**	91.40	10.00	-	101.40	-	-
II	**Other income**	14.97	6.17	2.17	21.14	5.58	16.98
III	**Total Income (I + II)**	**106.37**	**16.17**	**2.17**	**122.54**	**5.58**	**16.98**
IV	**Expenses:**						
	Cost of materials consumed	-	-	-	-	-	-
	Purchases of stock-in-trade	0.00	-	-	-	-	0.0
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	-	-	-	-	0.0
	Employee benefits expense	96.07	79.20	4.14	175.27	6.57	46.77
	Finance costs	32.99	14.39	0.04	47.38	0.04	0.20
	Depreciation and amortisation expense	0.00	-	-	-	-	0.00
	Other expenses	23.28	11.15	28.91	34.43	55.24	89.75
	Total Expenses	**152.34**	**104.73**	**33.08**	**257.07**	**61.84**	**136.71**
V	**Profit before exceptional items and tax (III - IV)**	(45.96)	(88.57)	(30.92)	(134.53)	(56.26)	(119.73)
VI	**Exceptional items** - Profit On Sale of Property Plant & Equipment	-	-	-	-	-	-
VII	**Profit before tax (V - VI)**	(45.96)	(88.57)	(30.92)	(134.53)	(56.26)	(119.73)
VIII	**Tax expense:**						
	(1) Current tax	-	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-	-
	(3) Income tax relating to earlier Years	-	-	-	-	-	-
IX	**Profit for the period (VII - VIII)**	(45.96)	(88.57)	(30.92)	(134.53)	(56.26)	(119.73)
X	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified	-	-	-	-	-	-
XI	**Total Comprehensive Income for the period (IX + X)**	**(45.96)**	**(88.57)**	**(30.92)**	**(134.53)**	**(56.26)**	**(119.73)**
XII	Paid Up Equity Share Capital	4,802.19	4,802.19	750.00	4,802.19	750.00	4,802.19
XIII	Face Value Of Equity Shares	10.00	10.00	10.00	10.00	10.00	10.00
XIV	Earnings per equity share (for continuing operations) - Basic	(0.10)	(0.18)	(0.41)	(0.28)	(0.75)	(1.18)
XIV	Earnings per equity share (for continuing operations) - Diluted	(0.10)	(0.18)	(0.41)	(0.28)	(0.75)	(1.18)

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS LIMITED)

Mr. Kaushal Uttam Shah
Managing Director

ARVAYA HEALTHCARE LIMITED

DIN: 02175130
Place: Sangli
Date: 13/11/2026

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS LIMITED)

CIN: L86100AS1985PLC002323
Reg. Office- NIRVANA Co Working Spaces, Mezzanine floor, Itag Plaza, ABC, G S Road, Guwahati, Dispur, Kamrup, Gmc, Assam , India 781005
Ph No: +91 7066670199 Email: compliance@arvayahealth.com Website:www.arvayahealth.com

STATEMENT OF ASSETS & LIABILITIES (BALANCE SHEET)

(₹ in Lacs)

	Particulars	As At 30-09-2026	As At 31-03-2026
I	**ASSETS**		
	A. Non-current assets		
	Property, Plant and Equipment	-	-
	Capital work-in-progress		
	Investment property		
	Goodwill		
	Other intangible assets		
	Intangible assets under development	7.15	
	Biological assets other than bearer plants		
	Financial assets		
	(i) Investments	6,078.23	6,078.23
	(ii) Trade receivables		
	(iii) Loans & Advances	-	-
	(iv) Other financial assets	-	
	Deferred tax assets (net)	-	-
	Other non-current assets		
	Total Non Current Assets...	**6,085.38**	**6,078.23**
	B. Current assets		
	Inventories		
	Financial assets		
	(i) Cash and cash equivalents	95.87	1.51
	(ii) Trade receivables	90.25	
	(iii) Bank balances other than (iii) above		
	(iv) Short Term Advances	365.00	490.00
	(v) Loans	623.76	208.10
	(vi) Other financial assets	40.59	40.59
	Current tax assets (net)		
	Other current assets	19.39	18.46
	Total Current Assets...	**1,234.86**	**758.65**
	Total Assets...	**7,320.24**	**6,836.88**

II	**EQUITY AND LIABILITIES**		
	A. Equity		
	(a) Equity share capital	4,802.19	4,802.19
	(b) Other equity	757.73	997.26
	Equity Attributable to Shareholders...	**5,559.92**	**5,799.45**
	B. Liabilities		
	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings		
	(ii) Trade payables		
	(iii) Other financial liabilities		
	(b) Provisions		
	(c) Deferred tax liabilities (net)		
	(d) Other non-current liabilities		
	Total Non Current Liabilities...	-	-
	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	1,603.19	252.00
	(ii) Trade payables		
	A) total outstanding dues of micro enterprises and small enterprises		
	(B) total outstanding dues of creditors other than micro and small enterprises		
	(iii) Other financial liabilities	5.08	0.30
	(b) Other current liabilities	117.69	769.25
	(c) Provisions	34.36	15.89
	(d) Current tax liabilities (net)		
	Total Current Liabilities...	**1,760.32**	**1,037.43**
	Total Equity and Liabilities...	**7,320.24**	**6,836.88**

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS LIMITED)

ARVAYA HEALTHCARE LIMITED

Mr. Kaushal Uttam Shah
Managing Director
DIN: 02175130

Place: Sangli
Date: 13/11/2026

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS LIMITED)

CIN: L86100AS1985PLC002323

Reg. Office- NIRVANA Co Working Spaces, Mezzanine floor, Itag Plaza, ABC, G S Road, Guwahati, Dispur, Kamrup, Gmc, Assam , India 781005

Ph No: +91 7066670199 Email: compliance@arvayahealth.com Website:www.arvayahealth.com

Unaudited Statement of Cash Flow for the Half Year Ended 30th September,2026

(₹ in Lacs)

SR No.	Particulars	Unaudited		Audited
		Period Ended 30-09-2026	Period Ended 30-09-2025	Year Ended 31-03-2026
	A. Cash Flows from Operating Activities			
	Net Profit before Tax	(134.53)	(56.26)	(119.73)
			-	
	Adjustments for:		-	
	Depreciation and Amortisation Expense	-	-	-
	Finance Costs	47.38	0.04	0.20
	Interest Income	(21.14)	(5.58)	(16.98)
	Debit Balances Written Off	-	-	22.75
	(Profit)/Loss on Sale of Property, Plant & Equipment	-	-	-
	Asset Written Off	-	-	-
	Operating Profit before Working Capital Changes	**(108.29)**	**(61.80)**	**(113.77)**
			-	
	Changes in Working Capital:		-	
	(Increase)/Decrease in Non Current Investments	-	-	-
	(Increase)/Decrease in Long Term Loans & Advances	-	(465.00)	25.00
	(Increase)/Decrease in Inventories	-	-	-
	(Increase)/Decrease in Trade Receivables	(90.25)	-	-
	(Increase)/Decrease in Short Term Advances	-	(124.75)	22.08
	(Increase)/Decrease in Short Term Loans	-		-
	(Increase)/Decrease in Other Current Financial Assets	-		(40.59)
	(Increase)/Decrease in Other Current Assets	(0.93)	(52.74)	(12.88)
	(Increase)/Decrease in Other Non Current Financial Assets	-	-	-
	Increase/(Decrease) in Other Current Financial Liability	98.45		18.05
	Increase/(Decrease) in Trade Payable	4.78		0.30
	Increase/(Decrease) in Other Liabilities	14.96	0.32	10.93
			-	
	Cash Generated from Operations	**(81.28)**	**(703.97)**	**(90.90)**
	Income Taxes Paid (Net)	-	-	-
A.	**Net Cash from Operating Activities**	**(81.28)**	**(703.97)**	**(90.90)**
	B. Cash Flows from Investing Activities			
	Intangible Assets under Development (IAUD)	(7.15)	-	-
	Value of Property, Plant and Equipment Sold	-	-	-
	Refund of Advance given for purchase of property	125.00		
	Advance for purchase of property	-	-	(490.00)
	Short Term Loan to Subsidiary	(645.00)		(51.11)
	Repayment of Short Term Loan by Subsidiary	200.00		
	Short Term Loan to Related Party	-		(156.99)
	Repayment of Short Term Loan to Related Party	50.00		
	Investment In Subsidiary	(750.00)	-	(250.00)
	Interest Received	0.47	5.58	16.98
B.	**Net Cash from Investing Activities**	**(1,026.68)**	**5.58**	**(931.11)**
	C. Cash Flows from Financing Activities			
	Proceeds from Borrowings	1,713.50		252.00
	Repayment of Borrowings	(406.09)		
	Proceeds from Issue of Equity Shares	-	562.50	562.50
	Equity Related Expenses	(105.00)		(61.34)
	Finance Costs Paid	(0.08)	(0.04)	(0.20)
C.	**Net Cash from/(used in) Financing Activities**	**1,202.33**	**562.46**	**752.96**
D.	**Net Increase/(Decrease) in Cash & Cash Equivalents (A + B + C)**	**94.37**	**(135.93)**	**(269.05)**
	Cash & Cash Equivalents at Beginning	1.51	270.56	270.56
	Cash & Cash Equivalents at End Period	**95.87**	**134.63**	**1.51**

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS LIMITED)

Mr. Kaushal Uttam Shah
Managing Director
DIN: 02175130

ARVAYA HEALTHCARE LIMITED

Place: Sangli
Date: 13/11/2026

Notes To Standalone Financials

1. The standalone financial results of the Company for the **quarter and half year ended September 30, 2026** have been reviewed and recommended by the **Audit Committee** and approved by the **Board of Directors** of the Company at their respective meetings held on **November 13, 2026**.

2. **Change in Name of the Company**

   Pursuant to approval granted by the Registrar of Companies, Ministry of Corporate Affairs, the name of the Company has been changed from **"Bijoy Hans Limited"** to **"Arvaya Healthcare Limited"** with effect from **May 11, 2026**, consequent to which the Memorandum of Association and Articles of Association of the Company stand amended accordingly.

3. **Increase in Authorised Share Capital**

   The Board of Directors of the Company, at its meeting held on **March 17, 2026**, approved the increase in the Authorised Share Capital of the Company from **₹60,00,00,000 (Rupees Sixty Crores Only)**, divided into **6,00,00,000 (Six Crore) equity shares of ₹10/- each**, to **₹200,00,00,000 (Rupees Two Hundred Crores Only)**, divided into **20,00,00,000 (Twenty Crore) equity shares of ₹10/- each**, **Subsequently** the same was approved by the shareholders on April 19, 2026.

4. **Basis of Preparation**

   These unaudited standalone financial results of the Company for the **quarter and half year ended September 30, 2026** have been prepared in accordance with **Indian Accounting Standard 34 "Interim Financial Reporting"** prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended), Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Statutory Auditors have carried out a limited review of these results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

5. **Preferential Issue of Equity Shares**

   Pursuant to the approval of the Board of Directors dated July 11, 2026, the approval of the shareholders obtained through Postal Ballot on August 13, 2026, and the in-principle approval granted by BSE Limited vide its letter bearing reference no. LOD/PREF/KS/FIP/920/2026-27 dated October 12, 2026, the Board of Directors of the Company, at its meeting held on October 24, 2026, allotted 38,71,854 fully paid-up equity shares of face value of ₹10/- each at an issue price of ₹40/- per share (including a premium of ₹30/- per share), aggregating to ₹15,48,74,160/-, on a preferential basis to 47 shareholders of Sushodha Institute of Gastroenterology Private Limited ("SIGPL"), for

consideration other than cash, pursuant to a share swap arrangement. Consequent to the said allotment, the paid-up equity share capital of the Company increased from ₹48,02,18,570/- comprising 4,80,21,857 equity shares to ₹51,89,37,110/- comprising 5,18,93,711 equity shares. The aforesaid allotment was made subsequent to the reporting date and, accordingly, has no impact on the financial results for the quarter and half year ended September 30, 2026.

6. **Proposed Rights Issue**

The Board of Directors, at its meeting held on **July 11, 2026**, approved the proposed Rights Issue of partly paid-up equity shares of the Company to the eligible equity shareholders, for an amount aggregating up to **₹21,000.00 lakhs (Rupees Two Hundred Ten Crore only)**, assuming full subscription, allotment and receipt of all call monies, pursuant to Section 62(1)(a) of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

At its meeting held on **November 4, 2026** (as revised vide intimation dated November 6, 2026), the Board authorised the Rights Issue Committee to review, finalise, approve and adopt the Draft Letter of Offer and to file it with BSE Limited, the Designated Stock Exchange, along with the application for in-principle approval. The final terms of the Rights Issue will be decided separately and are subject to regulatory approvals.

7. **Acquisition of Sushodha Institute of Gastroenterology Private Limited (Subsequent Event)**

On **November 1, 2026**, i.e. after the reporting date, the Company completed the acquisition of **1,84,374 equity shares**, constituting **100%** of the equity share capital of **Sushodha Institute of Gastroenterology Private Limited ("SIGPL")**, consequent to which SIGPL has become a wholly owned subsidiary of the Company with effect from that date. The consideration was discharged by the allotment of 38,71,854 equity shares of the Company to the shareholders of SIGPL on a share swap basis, as stated in the preceding note. This is a non-adjusting event after the reporting period in terms of **Ind AS 10 – Events after the Reporting Period** and accordingly has no impact on these results.

8. **Principal Business Criteria — Transitional Fulfilment and Regulatory Status**

The financial assets and financial income of the Company as at 31st March 2026 satisfy the Principal Business Criteria (PBC) prescribed under the applicable RBI Directions, solely on account of acquisition of healthcare subsidiaries on 4th March 2026 (27 days prior to year end), representing a transitional position arising from the Company's business restructuring. The Company has obtained an independent legal opinion opining that it is not required to obtain a Certificate of Registration as a Non-Banking Financial Company under Section 45-IA of the Reserve Bank of India Act, 1934.

The Company has commenced and continued revenue-generating healthcare operations from Q1 FY 2026-27 onwards. The Company does not carry on, and does not intend to carry on, Non-Banking Financial Company activities as its principal business.

9. Previous period figures have been regrouped / reclassified wherever necessary to conform to the current period's classification and presentation, in accordance with **Ind AS 1 – Presentation of Financial Statements**.

For and on behalf of
ARVAYA HEALTHCARE LTD
(Formerly Known as BIJOY HANS LTD)

ARVAYA HEALTHCARE LIMITED

Mr. Kaushal Uttam Shah
Managing Director
DIN: 02175130
Date: 13/11/2026
Place: Sangli

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of Arvaya Healthcare Limited (formerly known as Bijoy Hans Limited) for the Quarter and Half Year ended 30th September 2026, pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
Arvaya Healthcare Limited
(formerly known as Bijoy Hans Limited)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Arvaya Healthcare Limited (formerly known as Bijoy Hans Limited) ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter and half year ended 30th September 2026 ("the Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. The Holding Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable

4. The Statement includes the results of the following entities:

Entity	Name	Relationship
Holding Company	Arvaya Healthcare Limited (formerly known as Bijoy Hans Limited)	Listed Entity
Subsidiary	Arvaya Healthtech and Wellness Private Limited	Wholly Owned Subsidiary of AHL

Entity	Name	Relationship
Subsidiary	Tec-pool Solutions Private Limited	Wholly Owned Subsidiary of AHL
Subsidiary	Health Secure Hospitals Private Limited	Wholly Owned Subsidiary of AHL
Step-down Subsidiary	Health Secure Hospital Care & Solutions Private Limited	Subsidiary of Health Secure Hospitals Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Consolidated Financial Results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. **Other Matter:**

(i) We did not review the unaudited standalone financial results of Tec-pool Solutions Private Limited ("TPSPL"), a wholly owned subsidiary, included in the Statement, whose financial results, before consolidation adjustments, reflect total assets of ₹ 47.42 lakhs as at 30th September 2026, total revenues of ₹ 2 lakhs and ₹ 4 lakhs, total net profit/(loss) after tax of ₹ (0.93) lakhs and ₹ 1.03 lakhs and total comprehensive income/(loss) of (0.93) lakhs and ₹ 1.03 lakhs or the quarter and half year ended 30th September 2026 respectively, and net cash inflow/(outflow) of ₹ 0 lakhs for the half year ended 30th September 2026, as considered in the Statement. These financial results have been reviewed by other auditors, whose review report has been furnished to us by the Management, and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of TPSPL, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For
KHIRE KHANDEKAR & KIRLOSKAR
CHARTERED ACCOUNTANTS
FRN: 105148W

KEDAR GAJANAN PHATAK
Digitally signed by KEDAR GAJANAN PHATAK
Date: 2026.11.13 16:04:51 +05'30'

KHIRE KHANDEKAR & KIRLOSKAR
CHARTERED ACCOUNTANTS
FRN-105148W
SANGLI

K. G. PHATAK
Partner
M. No.: 104106
Place: Sangli
Date: 13/11/2026
UDIN:26104106RSNJXS6224

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS LTD)
CIN: L86100AS1985PLC002323
Regd. Office: NIRVANA Co Working Spaces, Mezzanine floor, Itag Plaza, ABC, G S Road, Guwahati, Dispur, Kamrup, Gmc, Assam, India 781005
Ph No: +91 7066670199 Email: compliance@arvayahealth.com Website: https://www.arvayahealth.com/

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026

(Amount in ₹ Lakhs)

Particulars	Quarter ended			Half year ended		Year ended
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. INCOME						
Revenue from operations	4,027.99	2,990.67	-	7,018.66	-	911.33
Other income	52.72	18.90	2.17	71.62	5.58	139.95
Total income (I)	**4,080.72**	**3,009.57**	**2.17**	**7,090.29**	**5.58**	**1,051.28**
II. EXPENSES						
Cost of materials consumed	244.46	151.57	-	396.04	-	61.99
Purchases of stock-in-trade	490.58	386.87	-	877.45	-	99.90
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(78.34)	(35.90)	-	(114.24)	-	(35.15)
Direct expenses	1,391.24	1,071.70	-	2,462.94	-	318.78
Employee benefits expense	777.45	547.41	4.14	1,324.86	6.56	189.53
Finance costs	167.33	139.26	0.04	306.59	0.04	41.39
Depreciation and amortisation expense	62.49	59.65	-	122.15	-	15.40
Depreciation on Right-of-Use assets	214.55	160.55	-	375.10	-	46.16
Impairment losses (incl. goodwill)	-	-	-	-	-	-
Net loss on de-recognition of financial assets at amortised cost	-	-	-	-	-	-
Net loss on reclassification of financial assets	-	-	-	-	-	-
Other expenses	678.56	472.50	28.91	1,151.06	55.24	203.75
Total expenses (II)	**3,948.33**	**2,953.62**	**33.09**	**6,901.94**	**61.84**	**941.88**
Profit/(loss) before share of associates / JVs, exceptional items and tax (I-II)	**132.39**	**55.95**	**(30.92)**	**188.34**	**(56.26)**	**109.40**
Share of profit/(loss) of associates / joint ventures	-	-	-	-	-	-
Profit/(loss) before exceptional items and tax	**132.39**	**55.95**	**60.00**	**188.34**	**(56.26)**	**109.40**
Exceptional items - gain/(loss)	-	-	-	-	-	-
Profit/(loss) before tax	**132.39**	**55.95**	**(30.92)**	**188.34**	**(56.26)**	**109.40**
Tax expense						
Current tax	-	-	-	-	-	-
Deferred tax	(4.38)	2.72	-	(1.66)	-	19.01
Income tax relating to earlier years	-	-	-	-	-	-
Total tax expense	**(4.38)**	**2.72**	**-**	**(1.66)**	**-**	**19.01**
Profit/(loss) for the period from continuing operations	**136.77**	**53.23**	**(30.92)**	**190.00**	**(56.26)**	**90.38**
Profit/(loss) from discontinued operations	-	-	-	-	-	-
Tax expense of discontinued operations	-	-	-	-	-	-
Profit/(loss) for the period	**136.77**	**53.23**	**(30.92)**	**190.00**	**(56.26)**	**90.38**
OTHER COMPREHENSIVE INCOME						
Items that will not be reclassified to profit or loss	3.19	2.19	-	5.37	-	0.73
Income tax on items not reclassified (tax charge as negative)	(0.80)	(0.55)	-	(1.35)	-	-
Items that will be reclassified to profit or loss	-	-	-	-	-	-
Income tax on items to be reclassified (tax charge as negative)	-	-	-	-	-	-
Other comprehensive income, net of tax	**2.38**	**1.64**	**-**	**4.02**	**-**	**0.73**
Total comprehensive income for the period	**139.16**	**54.87**	**(30.92)**	**194.02**	**(56.26)**	**91.11**
Attribution						
Profit for the period attributable to: Non-controlling interests	14.41	14.78	-	29.19	-	20.14
Profit for the period attributable to: Owners of the Company	122.36	38.46	(30.92)	160.82	(56.26)	70.24
Other comprehensive income attributable to: Non-controlling interests	0.23	0.15	-	0.38	-	0.07
Other comprehensive income attributable to: Owners of the Company	2.16	1.48	-	3.64	-	0.66
Total comprehensive income attributable to: Non-controlling interests	14.64	14.93	-	29.57	-	20.21
Total comprehensive income attributable to: Owners of the Company	124.52	39.94	(30.92)	164.46	(56.26)	70.90
Paid-up equity share capital (face value ₹10 per share)	4,802.19	4,802.19	750.00	4,802.19	750.00	4,802.19
Earnings per equity share (₹) - continuing and discontinued operations (quarterly figures not annualised)						
Basic	0.25	0.08	0.41	0.33	0.75	0.69
Diluted	0.25	0.08	0.41	0.33	0.75	0.69

ARVAYA HEALTHCARE LIMITED

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS

Mr. Kaushal Uttam Shah
Managing Director
DIN: 02175130

Place: Sangli
Date: 13/11/2026

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS LTD)

CIN: L86100AS1985PLC002323

Regd. Office: NIRVANA Co Working Spaces, Mezzanine floor, Itag Plaza, ABC, G S Road, Guwahati, Dispur, Kamrup, Gmc, Assam, India 781005

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30 SEPTEMBER 2026

Amount in ₹ Lakhs

Particulars	As at 30.09.2026 (Unaudited)	As at 31.03.2026 (Audited)
ASSETS		
1. Non-current assets		
Property, Plant and Equipment	2,658.02	2,381.28
Right-of-Use assets	5,279.54	3,989.13
Capital work-in-progress	-	-
Investment property	-	-
Goodwill	2,032.27	2,032.27
Other intangible assets	797.87	801.71
Intangible assets under development	28.77	-
Biological assets other than bearer plants	-	-
Financial assets		
Investments	13.25	13.25
Trade receivables	-	-
Loans & advances	-	-
Other financial assets	716.51	200.41
Deferred tax assets (net)	457.73	457.43
Other non-current assets	164.50	376.33
Total non-current assets	**12,148.46**	**10,251.79**
2. Current assets		
Inventories	303.94	189.70
Financial assets		
Investments	2.88	2.71
Trade receivables	703.65	219.65
Cash and cash equivalents	279.21	234.59
Bank balances other than above	-	-
Loans & advances	527.58	156.99
Other short term advances	-	-
Other financial assets	332.17	622.66
Current tax assets (net)	-	0.01
Other current assets	3,016.84	2,384.31
Total current assets	**5,166.27**	**3,810.61**
Assets held for sale / included in disposal group(s)	-	-
TOTAL ASSETS	**17,314.74**	**14,062.40**

EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,802.19	4,802.19
Instruments entirely equity in nature	-	-
Other equity	1,247.36	1,187.90
Non-controlling interests	346.19	316.62
Total equity	**6,395.73**	**6,306.71**
Liabilities		
1. Non-current liabilities		
Financial liabilities		
Borrowings	1,432.75	804.87
Lease liabilities	3,844.72	3,543.59
Trade payables	-	-
Other financial liabilities	-	-
Provisions	163.65	140.35
Deferred tax liabilities (net)	-	-
Other non-current liabilities	-	-
Total non-current liabilities	**5,441.12**	**4,488.81**
2. Current liabilities		
Financial liabilities		
Borrowings	1,701.08	251.94
Lease liabilities	1,485.34	337.58
Trade payables	857.23	1,140.90
Other financial liabilities	333.68	890.69
Other current liabilities	614.47	555.95
Provisions	486.10	89.82
Current tax liabilities (net)	-	-
Total current liabilities	**5,477.89**	**3,266.88**
Liabilities included in disposal group(s) held for sale	-	-
TOTAL EQUITY AND LIABILITIES	**17,314.74**	**14,062.40**

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS LIMITED)

ARVAYA HEALTHCARE LIMITED

Mr. Kaushal Uttam Shah
Managing Director
DIN: 02175130

Place: Sangli
Date: 13/11/2026

ARVAYA HEALTHCARE LIMITED

CIN: L86100AS1985PLC002323

Regd. Office: NIRVANA Co Working Spaces, Mezzanine floor, Itag Plaza, ABC, G S Road, Guwahati, Dispur, Kamrup, Gmc, Assam, India 781005

Ph No: +91 7066670199 Email: compliance@arvayahealth.com Website: https://www.arvayahealth.com/

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2026

(Amount in ₹ Lakhs)

Particulars	Half year ended 30.09.2026 (Unaudited)	Half year ended 30.09.2025 (Unaudited)	Year ended 31.03.2026 (Audited)
A. Cash flows from operating activities			
Net profit before tax	188.34	(56.26)	109.40
Adjustments for:			
Depreciation and amortisation expense	122.15	-	15.40
Depreciation on Right-of-Use assets	375.10	-	46.16
Finance costs	306.59	0.04	42.87
Impairment losses (incl. goodwill impairment)	-	-	-
Interest income	(22.77)	(5.58)	(26.92)
Interest income on security deposits	(17.15)	-	(1.40)
Unrealised gain on mutual funds	(0.17)	-	(0.11)
Liabilities / provisions no longer required written back	(31.50)	-	(113.01)
Debit balances written off	-	-	25.53
(Profit)/loss on sale of property, plant and equipment	-	-	-
Asset written off	-	-	-
Other non-cash adjustments (OCI remeasurement)	5.37	-	-
Operating profit before working capital changes	**925.95**	**(61.80)**	**97.93**
Changes in working capital:			
(Increase)/decrease in non-current investments	-	-	-
(Increase)/decrease in long-term loans & advances	-	(465.00)	25.00
(Increase)/decrease in inventories	(114.24)	-	(65.44)
(Increase)/decrease in trade receivables	(659.01)	-	(82.79)
(Increase)/decrease in contract assets (unbilled revenue)	-	-	3.38
(Increase)/decrease in short-term advances	-	(124.75)	22.08
(Increase)/decrease in short-term loans	-	-	(51.11)
(Increase)/decrease in other current financial assets	-	-	(50.72)
(Increase)/decrease in other current assets	(430.13)	(52.74)	38.65
(Increase)/decrease in other non-current financial assets	211.86	-	-
Increase/(decrease) in other financial liabilities and other current liabilities	232.17	-	17.11
Increase/(decrease) in contract liabilities (advances from customers)	(0.70)	-	(149.17)
Increase/(decrease) in trade payables	251.43	-	397.28
Increase/(decrease) in other liabilities (included in C24 above)	-	0.32	6.21
Non-cash effect of liabilities written back (reclassified)	-	-	111.01
Increase/(decrease) in provisions	398.56	-	-
Cash generated from operations	**815.89**	**(703.97)**	**319.43**
Income taxes paid (net of refunds) - enter as negative	0.05	-	-
Net cash from / (used in) operating activities (A)	**815.94**	**(703.97)**	**319.43**
B. Cash flows from investing activities			
Purchase of property, plant and equipment / intangibles / CWIP	(403.95)	-	(465.94)
Purchase of investments	-	-	(14.33)
Security deposits given	(588.27)	-	(1.20)
Proceeds from sale of property, plant and equipment	-	-	-
Investment in subsidiaries / acquisition of businesses (net of cash acquired)	-	-	(250.00)
Payment of outstanding purchase consideration - Health Secure acquisition	(750.00)	-	-
Interest received	0.66	5.58	28.32
Advances to lessors and bank deposits not considered cash equivalents (net)	(18.40)	-	-
Advance for purchase of property refunded / (paid)	125.00		-
Advance for purchase of property			(490.00)
Loans given to related parties / others	-		(156.99)
Loans repaid by related parties / others	50.00		-
Net cash from / (used in) investing activities (B)	**(1,584.95)**	**5.58**	**(1,350.15)**

C. Cash flows from financing activities			
Proceeds from issue of equity shares	-	562.50	562.50
Proceeds from short-term borrowings	-	-	252.00
Proceeds from secured borrowings	-	-	178.52
Repayment of secured borrowings	-	-	(11.10)
Proceeds from borrowings (secured and unsecured)	1,854.93	-	2.00
Repayment of borrowings (secured and unsecured)	(462.99)	-	(13.04)
Repayment of lease liabilities (principal portion)	(185.13)	-	(23.37)
Loan processing charges paid	-	-	(1.33)
Interest paid on lease liabilities	(208.65)	-	(32.76)
Equity-related (share issue) expenses	(105.00)	-	(61.34)
Finance costs paid	(79.53)	(0.04)	(2.04)
Dividends paid	-	-	-
Other financing activities (specify)	-	-	-
Net cash from / (used in) financing activities (C)	**813.63**	**562.46**	**850.04**
Net increase / (decrease) in cash and cash equivalents (A+B+C)	**44.62**	**(135.93)**	**(180.68)**
Opening cash and cash equivalents	234.59	270.56	415.27
Closing cash and cash equivalents	**279.21**	**134.63**	**234.59**

ARVAYA HEALTHCARE LIMITED
(Formerly Known as BIJOY HANS LIMITED)

ARVAYA HEALTHCARE LIMITED

Mr. Kaushal Uttam Shah
Managing Director
DIN: 02175130

Place: Sangli
Date: 13/11/2026

Notes To Consolidated Financials-

1. The Consolidated financial results of the Company for the **quarter and half year ended September 30, 2026** have been reviewed and recommended by the **Audit Committee** and approved by the **Board of Directors** of the Company at their respective meetings held on **November 13, 2026**.

2. **Change in Name of the Company**

   Pursuant to approval granted by the Registrar of Companies, Ministry of Corporate Affairs, the name of the Company has been changed from **"Bijoy Hans Limited"** to **"Arvaya Healthcare Limited"** with effect from **May 11, 2026**, consequent to which the Memorandum of Association and Articles of Association of the Company stand amended accordingly.

3. **Increase in Authorised Share Capital**

   The Board of Directors of the Company, at its meeting held on **March 17, 2026**, approved the increase in the Authorised Share Capital of the Company from **₹60,00,00,000 (Rupees Sixty Crores Only)**, divided into **6,00,00,000 (Six Crore) equity shares of ₹10/- each**, to **₹200,00,00,000 (Rupees Two Hundred Crores Only)**, divided into **20,00,00,000 (Twenty Crore) equity shares of ₹10/- each**, **Subsequently** the same was approved by the shareholders on April 19, 2026.

4. **Basis of Preparation**

   These unaudited consolidated financial results of Arvaya Healthcare Limited ("the Holding Company") and its subsidiaries (together "the Group") for the **quarter and half year ended September 30, 2026** have been prepared in accordance with **Indian Accounting Standard 34 "Interim Financial Reporting"** prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended), Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Statutory Auditors have carried out a limited review of these results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

5. **Basis of Consolidation and Comparatives**

The consolidated results include the results of the Holding Company and its subsidiaries, namely **Health Secure Hospitals Private Limited (100.00%)**, **Arvaya Healthtech and Wellness Private Limited (100.00%)** and **Tec-pool Solutions Private Limited (100.00%)**, and its step-down subsidiary **Health Secure Hospital Care & Solutions Private Limited (90.56%, held through Health Secure Hospitals Private Limited)**. All subsidiaries have been consolidated line-by-line from the date of acquisition, being **March 4, 2026**.

The Group came into existence on March 4, 2026. Accordingly, the figures for the quarter and half year ended September 30, 2025 represent the standalone results of the Holding Company as published and are not comparable with the figures for the current periods. The figures for the year ended March 31, 2026 include the results of the subsidiaries only for the period from March 4, 2026 to March 31, 2026.

6. The Group operates in the business of **healthcare services**, constituting the only reportable segment in accordance with **Ind AS 108 – Operating Segments**. **Tec-Pool Solutions Private Limited ("TPSPL")** utilises its technology platform and intellectual property exclusively for internal use within the Group and does not operate as an independent revenue-generating segment. Since the Group operates in a single reportable segment, no further segment disclosures are required under **Ind AS 108** and **Part A, Clause L of Schedule IV to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**.

7. **Preferential Issue of Equity Shares**

Pursuant to the approval of the Board of Directors dated July 11, 2026, the approval of the shareholders obtained through Postal Ballot on August 13, 2026, and the in-principle approval granted by BSE Limited vide its letter bearing reference no. LOD/PREF/KS/FIP/920/2026-27 dated October 12, 2026, the Board of Directors of the Company, at its meeting held on October 24, 2026, allotted 38,71,854 fully paid-up equity shares of face value of ₹10/- each at an issue price of ₹40/- per share (including a premium of ₹30/- per share), aggregating to ₹15,48,74,160/-, on a preferential basis to 47 shareholders of Sushodha Institute of Gastroenterology Private Limited ("SIGPL"), for consideration other than cash, pursuant to a share swap arrangement. Consequent to the said allotment, the paid-up equity share capital of the Company increased from ₹48,02,18,570/- comprising 4,80,21,857 equity shares to ₹51,89,37,110/- comprising 5,18,93,711 equity shares. The aforesaid allotment was made subsequent to the reporting date and, accordingly, has no impact on the financial results for the quarter and half year ended September 30, 2026.

8. **Proposed Rights Issue**

The Board of Directors, at its meeting held on **July 11, 2026**, approved the proposed Rights Issue of partly paid-up equity shares of the Company to the eligible equity shareholders, for an amount aggregating up to **₹21,000.00 lakhs (Rupees Two Hundred Ten Crore only)**, assuming full subscription, allotment and receipt of all call monies, pursuant to Section 62(1)(a) of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

At its meeting held on **November 4, 2026** (as revised vide intimation dated November 6, 2026), the Board authorised the Rights Issue Committee to review, finalise, approve and adopt the Draft Letter of Offer and to file it with BSE Limited, the Designated Stock Exchange, along with the application for in-principle approval. The final terms of the Rights Issue will be decided separately and are subject to regulatory approvals.

9. Previous period figures have been regrouped / reclassified wherever necessary to conform to the current period's classification and presentation, in accordance with **Ind AS 1 – Presentation of Financial Statements**.

For and on behalf of
ARVAYA HEALTHCARE LTD
(Formerly Known as BIJOY HANS LTD)

ARVAYA HEALTHCARE LIMITED

Mr. Kaushal Uttam Shah
Managing Director
DIN: 02175130
Date: 13/11/2026
Place: Sangli